ContraFect's CEO To Go On Medical Leave

ContraFect (NASDAQ:CFRX) announced that CEO Dr. Steven C. Gilman will take a medical leave starting on March 16.
As quoted in the press release:

Dr. Gilman will continue to serve as Chairman during his temporary leave of absence. He is expected to return to his CEO role in the third quarter of 2017.
The Company’s Board has established an Interim Office of the Chief Executive Officer for the duration of Dr. Gilman’s absence as CEO, consisting of the following executive officers of the Company: Cara Cassino, M.D., Executive Vice President of Research and Development and Chief Medical Officer; Natalie Bogdanos, General Counsel and Corporate Secretary; Michael Messinger, Senior Vice President, Finance; and Josh Muntner, Senior Vice President, Business Development, who will collectively assume the CEO duties on an interim basis, effective March 16, 2017. The Interim Office of the CEO will report directly to a newly formed subcommittee of the Board, designated the CEO Oversight Committee, consisting of directors Sol Barer, Ph.D., Dr. Gilman, Michael Otto, Ph.D. and Lisa Ricciardi.
“The Company’s senior management team has worked seamlessly together since I have been CEO, and I am confident that they will continue to drive ContraFect’s programs forward,” said Dr. Gilman. “I look forward to staying engaged with the Company by providing direction and oversight as part of my continuing role as Chairman and as a member of the CEO Oversight Committee,” continued Dr. Gilman.
About ContraFect
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to drug-resistant bacterial infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). In addition to CF-301, the company’s preclinical programs include potential novel lysins for the treatment of drug resistant gram-negative pathogens as well as a monoclonal antibody program targeted for the treatment of viral influenza.

Click here to read the full press release.